ClinicalTrials.Veeva

Menu

Three-Year Trial on a New Testosterone Gel

U

University Hospital Muenster

Status and phase

Unknown
Phase 3

Conditions

Hypogonadism

Treatments

Drug: Testosterone Gel Wolff

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00204269
IRM 2002/37
TGT-04/2002

Details and patient eligibility

About

The objective of the study is to examine the efficacy and tolerability of a three-year-Testosterone replacement therapy in hypogonadal patients as well as the patient's compliance. The replacement therapy will be performed with a new Testosterone Gel examined in previous trials as Testosteron Gel Wolff.

Full description

The objective of the study is to examine the efficacy and tolerability of a three-year-Testosterone replacement therapy in hypogonadal patients as well as the patient's compliance. The replacement therapy will be performed with a new Testosterone Gel examined in previous trials as Testosteron Gel Wolff (TGW).

A minimum of 100 patients will be recruited and evenly distributed to two treatment arms. 1st arm: dermal (non-scrotal) application of TGW. 2nd arm: scrotal application of TGW.

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

men with

  • hypergonadotropic hypogonadism
  • hypogonadotropic hypogonadism
  • late-onset hypogonadism

combined with an initial Testosterone serum level of < 11 nmol/l

Exclusion criteria

  • known or suspected carcinoma of the prostate
  • clinically relevant abnormalities in clinical chemistry or haematology
  • any severe medical conditions at the opinion of the investigator

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

15

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems